Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2345/0899-8205-45.2.126 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Improved survival of advanced melanoma patients receiving immunotherapy with concomitant antithrombotic therapy - A multicenter study on 2419 patients from the prospective skin cancer registry ADOReg.
Eur J Cancer
January 2025
Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany; Fleur Hiege Center for Skin Cancer Research, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany. Electronic address:
Background: Cancer immunotherapy has revolutionized melanoma treatment, but the high number of non-responders still emphasizes the need for improvement of therapy. One potential avenue for enhancing anti-tumor treatment is through the modulation of coagulation and platelet activity. Both have been found to play an important role in the tumor microenvironment, tumor growth and metastasis.
View Article and Find Full Text PDFChina Liver Transplant Registry plays an important role in liver transplantation.
Hepatobiliary Pancreat Dis Int
November 2024
Department of Hepatobiliary and Pancreatic Surgery, Department of Liver Transplantation, Shulan (Hangzhou) Hospital, Hangzhou 310003, China; Division of Hepatobiliary Pancreatic Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China; Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China; National Center for Healthcare Quality Management in Liver Transplant, Hangzhou 310003, China. Electronic address:
In China, liver transplantation is an important discipline in the field of organ transplantation. China Liver Transplant Registry (CLTR) is a scientific project that has been set up to advance surgical techniques and procedures and to improve both short- and long-term post-transplant follow-up and outcome of the liver recipients. CLTR also serves as a robust data support platform for the National Liver Transplant Quality Control Center in the quest to upscale its quality control protocols.
View Article and Find Full Text PDFUltrasound-Guided High-Intensity Focused Ultrasound Combined With PD-1 Blockade in Patients With Liver Metastases From Lung Cancer: Protocol for a Single-Arm Phase 2 Trial.
JMIR Res Protoc
November 2024
Respiratory Department, Xiangtan Central Hospital, Xiangtan, China.
Background: While immunotherapy has revolutionized oncological management, its efficacy in lung cancer patients with liver metastases remains limited, potentially due to the unique immunosuppressive microenvironment of the liver. Local liver treatment has been shown to enhance the immunotherapy response, and high-intensity focused ultrasound (HIFU), a minimally invasive local treatment, has demonstrated promising results in combination with immunotherapy. However, clinical data regarding HIFU in lung cancer with liver metastases are limited.
View Article and Find Full Text PDF[The modified hugging balloon technique].
G Ital Cardiol (Rome)
November 2024
S.C. Cardiologia, Ospedale S.G. Bosco, ASL Città di Torino, Torino.
Article Synopsis
- Percutaneous coronary intervention (PCI) has greatly improved treatments for coronary artery disease, but in-stent restenosis (ISR) remains a significant issue, especially when complicated by calcification.
- Various techniques exist for treating calcified ISR, including super-high-pressure balloon dilation, atherectomy methods, and intravascular lithotripsy (IVL).
- This case report discusses a patient with severe, calcified ISR in a large artery, showcasing the use of shockwave lithotripsy combined with balloon dilation to improve stent expansion, highlighting the effectiveness of innovative approaches for difficult ISR cases.
Long-term outcomes of PARP inhibitors in ovarian cancer: survival, adverse events, and post-progression insights.
ESMO Open
November 2024
Department of Oncology, Immuno-Oncology Service, University Hospital of Lausanne (CHUV-UNIL), Lausanne, Switzerland; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland; Agora Cancer Research Center, Lausanne, Switzerland. Electronic address:
Poly-ADP-ribose polymerase inhibitors (PARPis) have revolutionized the management of BRCA-mutated (BRCA) and homologous recombination deficiency (HRD)-positive ovarian cancer (OC). While long-term analyses clearly support the use of PARPi as maintenance therapy after first-line chemotherapy, recent data have raised concerns on detrimental overall survival (OS) in non-BRCA OC, a greater incidence of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), and unfavorable outcomes following subsequent platinum-based chemotherapy in pretreated OC patients. In this report we discuss the long-term follow-up results from phase III trials in pretreated OC patients, which led to the Food and Drug Administration's withdrawal of PARPi indications in this setting.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!